# Bond Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bond-biosciences

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.bond.bio
- Total disclosed funding: $12M
- Latest round: Series B (Dec 17, 2021)
- Investors on record: 1

## About

Bond Biosciences, Inc., based in New York, US, focuses on developing innovative non-absorbed oral therapeutics to address iron-related diseases, particularly targeting iron overload through advanced therapeutic solutions.Founded in 2016, Bond Biosciences, Inc. specializes in therapeutics aimed at treating iron overload conditions. The company is led by founders Cory Berkland and Michael Riley. Bond Biosciences has secured a total of USD 6.80 mn in funding through their Series B round, led by Collage Partners, with the latest deal occurring on December 17, 2021. The company's current valuation stands at USD 115.898 mn.Bond Biosciences, Inc. specializes in the development of innovative non-absorbed oral therapeutics, particularly focusing on the treatment of iron-related diseases. Their flagship product, BBI-001, targets iron overload associated with Hereditary Hemochromatosis by binding dietary iron in the gastrointestinal tract to inhibit its absorption. This aims to prevent serious health complications linked to unmanaged iron overload, such as liver disease and cardiovascular issues. Currently, BBI-001 is undergoing clinical trials, having demonstrated effectiveness in pre-clinical animal studies, and the company is exploring its technology's application for other ion-related diseases, primarily in North America.Bond Biosciences' revenue structure is anticipated to revolve around direct transactions with healthcare providers and potential partnerships with pharmaceutical distributors as the company advances its product offerings. It aims to establish a direct-to-consumer model for BBI-001, allowing access to the therapy upon regulatory approval. Revenue will be generated through sales of BBI-001 and may include service agreements or subscription models for ongoing treatment management. The structured transactions are expected to facilitate access to this therapeutic solution for patients suffering from iron overload conditions.In December 2021, Bond Biosciences, Inc. raised USD 6.80 mn in Series B funding led by returning investor Collage Partners. The company plans to utilize this funding to strengthen the development program for BBI-001 and advance its pipeline of non-absorbed oral therapies. As regulatory approvals are pursued, Bond Biosciences aims to expand its market reach, focusing on North America and potentially extending to other regions.

## Funding rounds

- Series B, Dec 17, 2021, $6.8M — Collage Partners
- Series A, Mar 20, 2021, $5M — Collage Partners

## Investors

- Collage Partners (https://capitalatlas.ai/funds/collage-partners) — Series A, Series B